Mitochonic Medical

Mitochonic Medical is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics that enhance mitochondrial function and cellular energy production. The company's lead candidate, Mitochonic Acid 5 (MA-5), is a mitochondria-homing drug that binds to the mitochondrial protein mitofilin to facilitate ATP synthase oligomerization and improve ATP production efficiency. MA-5 is currently being investigated in Phase 2 clinical trials for the treatment of mitochondrial diseases and has shown potential in preclinical models for a wide range of conditions, including Parkinson's disease, Duchenne muscular dystrophy, and Barth syndrome. By targeting the structural integrity of mitochondrial cristae, Mitochonic Medical aims to provide disease-modifying treatments for rare and age-related disorders driven by mitochondrial dysfunction.